[9]Wiviott S D, et al.New England Journal of Medicine, 2019, 380(4): 347-357. [10] M. Packer, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. Presented at 2020 ESC. [11]EMPA-Kidney Collaborative Group...
此外,未来研究需致力于为更广泛的T2DM患者群体制定有效策略,以阻止亚临床心脏疾病进展,从而降低HF的整体疾病负担。 参考文献:Diabetic myocardial disorder. A clinicalconsensus statement of the Heart Failure Association of the ESC and ...
[12].AHA 2024. Exploring Provider Hesitancy in Prescribing SGLT2 Inhibitor for Acute Heart Failure Patients: Insights from a Single-Center Teaching Hospital Survey. AHA 2024. [13].John J V McMurray, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J M...
Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week https://pubmed.ncbi.nlm.nih.gov/38199714/
Elderly patients with HF with reduced ejection fraction and renal failure: are SGLT2i a good option? AHA 2024. [7]. Tess Calcagno, et al. Impact of SGLT2 Inhibitors on Cardiovascular Outcomes Following Acute Myocardial Infarction with Heart Failure with Preserved Ejection Fraction: A Propensity-...
该Meta分析包含5项相关研究（EMPEROR- PRESERVED、VERTIS-CV、DECLARE-TIMI 58、SOLOIST-WHF、SCORED）、9726例舒张性心衰患者，其中5046例接受SGLT2i治疗，4680例应用安慰剂。来源：[1]Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-...
同样，CRONOS-ADM注册研究发现，糖尿病病程较长与冠心病患病率、范围和严重程度以及主要不良心血管和脑血管事件的风险相关。 总之，作者认为，糖尿病病程是考虑启动SGLT2i治疗成本获益的一个重要因素。 来源：[1] Siddiqi TJ, et al. Duration of Diabetes and Risk of Incident Heart Failure: Using the Past to ...
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database https://pubmed.ncbi.nlm.nih.gov/36054168/...
[4]Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med, 27 August 2022 [5]SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials....
[10] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019, 381(21):1995-2008. [11] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved...